NicOx

easybourse.com: La newsletter sur l'actualité de la bourse easybourse.com

NicOx Completes Enrollment Of Two Ambulatory Blood Pressure Measurement (ABPM) Studies For...

medicalnewstoday.com     21 hrs ago   13 related          

NicOx S.A. (Euronext Paris: COX) announced it has successfully completed the enrollment of 417 osteoarthritis (OA) patients with controlled hypertension in two clinical pharmacology studies in the United States, in line with...                

comments

                   

TOPIGEN Pharmaceuticals Completes Enrollment of Phase II Clinical Study of TPI ASM8 in Asthma

marketwire.com     21 hrs ago   2 related          

Clinical Study On-Track for Completion MONTREAL--(Marketwire - TOPIGEN Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, today announced the...                

comments

                   

Trophos appoints Damian Marron as Chief Executive Officer

pharmiweb.co.uk     Jul 3, 2008          

Marseille, June 12th, 2008 - Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced today the appointment of Damian Marron as Chief Executive...                

comments

Company and People Notes: SAFC Biosciences to Collaborate With Celltrion, USP Names K.V. Surendra...

pharmtech.com     Jun 19, 2008   2 related          

Company Notes Exeter, NH (June 12)—The board of directors of Bentley Pharmaceuticals, a specialty pharmaceutical company, approved the spin-off of its drug delivery business into a new publicly traded company to be called CPEX...                

comments

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

prnewswire.com     Jun 17, 2008   1 related          

NEW YORK, June 17 /PRNewswire/ -- Mergent, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange Traded Funds, today announced the quarterly rebalancing of the...                

comments

NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study For Naproxcinod At EULAR

medicalnewstoday.com     Jun 14, 2008   9 related          

NicOx S.A. (Euronext Paris: COX) announced an additional analysis of the blood pressure data from the 301 phase 3 study, showing a statistically significant difference between naproxcinod and naproxen in terms of the mean...                

comments

TOPIGEN Pharmaceuticals Appoints Jeremy Curnock Cook to Its Board of Directors

tmcnet.com     Jun 3, 2008   3 related          

MONTREAL, June 3 / MARKET WIRE/ -- TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, today announced the appointment of Jeremy Curnock Cook, MA, to...                

comments

NICOX : Number of voting rights as of May 29, 2008

euroinvestor.fr     May 30, 2008   10 related          

TRANSLATION FOR INFORMATION PURPOSES ONLYFORM FOR THE DECLARATION OF THE NUMBER OF VOTING RIGHTS(Article 222-12-5 of the " Règlement général " of the AMF)Autorités des marchés financiersDirection des Emetteurs17, place de la...                

comments

                   

NicOx Completes Patient Enrollment In Third Naproxcinod Pivotal Phase 3 Study

medicalnewstoday.com     May 29, 2008   8 related          

NicOx S.A. (Euronext Paris: COX) announced the completion of patient enrollment in the third pivotal phase 3 clinical trial for naproxcinod, in patients with osteoarthritis of the hip (the 303 study). 810 patients have been randomized in 120 clinical centers in North America and Europe in this...                

comments

                   
easybourse.com: La newsletter sur l'actualité de la bourse easybourse.com

NicOx announces departure of Damian Marron for CEO position (Marketwire)

yahoo.com     May 27, 2008   9 related          

SOPHIA ANTIPOLIS, FRANCE--(MARKET WIRE)--May 27, 2008 -- Sophia Antipolis, France. www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced that Damian Marron, Executive Vice President of Corporate Development, will be leaving the company on 30th May to become Chief Executive Officer of an...                

comments

1 2 3 4 next »